STERIS PLC (NYSE:STE) issued its earnings results on Tuesday. The medical equipment provider reported $0.85 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.05, Bloomberg Earnings reports. STERIS PLC had a return on equity of 11.12% and a net margin of 4.20%. The firm had revenue of $608 million for the quarter, compared to analysts’ expectations of $597.66 million. During the same quarter last year, the business earned $0.79 earnings per share. The company’s revenue was down 4.8% compared to the same quarter last year. STERIS PLC updated its FY18 guidance to $3.96-4.09 EPS.

STERIS PLC (NYSE:STE) opened at 82.21 on Tuesday. STERIS PLC has a 12-month low of $63.80 and a 12-month high of $83.54. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of 64.23 and a beta of 1.33. The company’s 50 day moving average price is $82.15 and its 200-day moving average price is $74.62.

Several research firms have recently weighed in on STE. Wellington Shields cut STERIS PLC from a “gradually accumulate” rating to a “hold” rating in a report on Monday, June 5th. BidaskClub cut STERIS PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research upgraded STERIS PLC from a “hold” rating to a “buy” rating and set a $92.00 target price on the stock in a research note on Tuesday, July 11th. Finally, KeyCorp upgraded STERIS PLC from a “sector weight” rating to an “overweight” rating and set a $89.00 target price on the stock in a research note on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. STERIS PLC has a consensus rating of “Buy” and a consensus target price of $84.00.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at

In related news, Director Michael B. Wood sold 4,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $81.50, for a total transaction of $326,000.00. Following the completion of the sale, the director now directly owns 26,131 shares of the company’s stock, valued at $2,129,676.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel A. Carestio sold 4,745 shares of the stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $80.08, for a total value of $379,979.60. The disclosure for this sale can be found here. Insiders have sold 30,340 shares of company stock valued at $2,432,704 over the last ninety days. 2.55% of the stock is currently owned by company insiders.

STERIS PLC Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Earnings History for STERIS PLC (NYSE:STE)

Receive News & Ratings for STERIS PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS PLC and related companies with's FREE daily email newsletter.